In Segment C, individuals will get ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally illness progression or even the participants are unable to tolerate the study drugs. - Participant eaten grapefruit or grapefruit goods within 3 days previous to https://hesiodk665wit8.laowaiblog.com/profile